X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7790) 7790
Publication (811) 811
Book Review (78) 78
Book Chapter (24) 24
Conference Proceeding (13) 13
Magazine Article (7) 7
Dissertation (6) 6
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6165) 6165
sirolimus - administration & dosage (4638) 4638
index medicus (4497) 4497
male (4159) 4159
female (3747) 3747
middle aged (2828) 2828
treatment outcome (2281) 2281
aged (2238) 2238
animals (2166) 2166
sirolimus - analogs & derivatives (2141) 2141
rapamycin (1922) 1922
cardiac & cardiovascular systems (1916) 1916
sirolimus (1902) 1902
immunosuppressive agents - administration & dosage (1741) 1741
drug-eluting stents (1675) 1675
everolimus (1570) 1570
stents (1465) 1465
sirolimus - therapeutic use (1454) 1454
sirolimus - pharmacology (1442) 1442
time factors (1337) 1337
adult (1329) 1329
transplantation (1116) 1116
oncology (1026) 1026
mice (1023) 1023
sirolimus - adverse effects (971) 971
coronary angiography (967) 967
stent (933) 933
follow-up studies (878) 878
paclitaxel - administration & dosage (872) 872
surgery (866) 866
restenosis (851) 851
immunosuppressive agents - therapeutic use (839) 839
cardiovascular agents - administration & dosage (837) 837
implantation (795) 795
risk factors (793) 793
thrombosis (781) 781
mammalian target (776) 776
prosthesis design (758) 758
coronary artery disease - therapy (730) 730
prospective studies (720) 720
mtor (712) 712
care and treatment (666) 666
cancer (659) 659
tor serine-threonine kinases - antagonists & inhibitors (651) 651
immunology (644) 644
pharmacology & pharmacy (641) 641
coronary restenosis - prevention & control (628) 628
immunosuppressive agents - adverse effects (596) 596
research (590) 590
angioplasty (555) 555
rats (550) 550
retrospective studies (547) 547
drug therapy, combination (543) 543
analysis (540) 540
angioplasty, balloon, coronary - instrumentation (532) 532
angioplasty, balloon, coronary - adverse effects (527) 527
therapy (523) 523
trial (512) 512
percutaneous coronary intervention (506) 506
cardiovascular (497) 497
dose-response relationship, drug (493) 493
abridged index medicus (491) 491
tor serine-threonine kinases - metabolism (485) 485
cyclosporine (483) 483
drug therapy (465) 465
angioplasty, balloon, coronary (457) 457
cell line, tumor (450) 450
kidney transplantation (444) 444
immunosuppressive agents - pharmacology (439) 439
cardiology (423) 423
aged, 80 and over (421) 421
drug delivery systems (420) 420
health aspects (420) 420
tacrolimus (414) 414
article (413) 413
antineoplastic combined chemotherapy protocols - therapeutic use (412) 412
signal transduction - drug effects (411) 411
coronary stenosis - therapy (401) 401
drug administration schedule (400) 400
drug-eluting stent (399) 399
coronary restenosis - etiology (397) 397
follow-up (395) 395
immunosuppression (395) 395
cell proliferation - drug effects (391) 391
efficacy (389) 389
drug-eluting stents - adverse effects (382) 382
risk assessment (378) 378
disease models, animal (371) 371
disease (369) 369
sirolimus - pharmacokinetics (368) 368
graft rejection - prevention & control (363) 363
kaplan-meier estimate (363) 363
inhibition (357) 357
tor serine-threonine kinases (355) 355
dosage and administration (354) 354
paclitaxel (341) 341
proteins (339) 339
registries (339) 339
apoptosis (336) 336
medicine & public health (335) 335
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7535) 7535
French (56) 56
Chinese (54) 54
German (44) 44
Japanese (38) 38
Spanish (34) 34
Russian (14) 14
Italian (9) 9
Polish (9) 9
Danish (5) 5
Portuguese (5) 5
Hungarian (4) 4
Czech (2) 2
Lithuanian (2) 2
Croatian (1) 1
Dutch (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2015, Volume 112, Issue 2, pp. E156 - E165
Current treatments to control pathological or unwanted immune responses often use broadly immunosuppressive drugs. New approaches to induce antigen-specific... 
Nanoparticles | Rapamycin | Anti-drug antibodies | Immune tolerance | Immunotherapy | THERAPEUTICS | anti-drug antibodies | IMMUNITY | TOLEROGENIC DENDRITIC CELLS | RISK-FACTORS | MULTIDISCIPLINARY SCIENCES | FACTOR-VIII | MECHANISMS | RESPONSES | immune tolerance | IMMUNOGENICITY | nanoparticles | UNRESPONSIVENESS | immunotherapy | rapamycin | Factor VIII - immunology | Oligodeoxyribonucleotides - administration & dosage | Nanoparticles - chemistry | Ovalbumin - immunology | Immunosuppression - methods | Nanocapsules - administration & dosage | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Hypersensitivity, Delayed - immunology | Nanocapsules - chemistry | Peptides - administration & dosage | Antigens - administration & dosage | CD4-Positive T-Lymphocytes - immunology | Immunity, Humoral | Peptide Fragments - immunology | Proteins - administration & dosage | Female | Immunosuppressive Agents - administration & dosage | Disease Models, Animal | Lactic Acid - chemistry | Peptides - chemistry | Hemophilia A - immunology | Peptide Fragments - administration & dosage | Peptides - immunology | Immune Tolerance | Hemophilia A - therapy | Hypersensitivity, Delayed - therapy | Antigens - chemistry | Proteins - immunology | Encephalomyelitis, Autoimmune, Experimental - therapy | Sirolimus - administration & dosage | Animals | Ovalbumin - administration & dosage | Recombinant Proteins - immunology | Polyglycolic Acid - chemistry | Encephalomyelitis, Autoimmune, Experimental - prevention & control | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Hemocyanins - administration & dosage | Proteins - chemistry | Antigens | Usage | Research | Health aspects | Immunological tolerance | Immunological research | Immunology | Polymers | Chemical synthesis | Immune system | Biological Sciences | PNAS Plus
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
The Journal of Physiology, ISSN 0022-3751, 04/2009, Volume 587, Issue 7, pp. 1535 - 1546
Journal Article
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2012, Volume 181, Issue 3, pp. 947 - 960
Journal Article
The Oncologist, ISSN 1083-7159, 04/2009, Volume 14, Issue 4, pp. 320 - 368
Contrast the current strengths and limitations of the three main slide‐based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast... 
Prognosis | CISH | IHC | FISH | Lapatinib | Review | HER‐2 | Trastuzumab | HER-2 | SURGICAL ADJUVANT BREAST | C-ERBB-2 ONCOPROTEIN EXPRESSION | TOPOISOMERASE-II-ALPHA | LONG-TERM SURVIVAL | IN-SITU HYBRIDIZATION | PATHOLOGICAL COMPLETE RESPONSE | CIRCULATING TUMOR-CELLS | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | C-ERB B-2 | NEOADJUVANT ENDOCRINE THERAPY | Immunohistochemistry | Humans | RNA, Messenger - analysis | Bevacizumab | Antibodies, Monoclonal, Humanized | Breast Neoplasms - chemistry | Anthracyclines - administration & dosage | In Situ Hybridization | Polymerase Chain Reaction | Female | Quinazolines - administration & dosage | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Everolimus | Sirolimus - analogs & derivatives | Biomarkers, Tumor - analysis | Pyrimidines - administration & dosage | Treatment Outcome | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Up-Regulation - drug effects | Sirolimus - administration & dosage | Taxoids - administration & dosage | Pyrazoles - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Neoplasm Staging | Practice Guidelines as Topic | Index Medicus
Journal Article